3.3. CXCL10 and CXCL9 in Cancer Therapy: Could Systemic Administration of These Chemokines Induce Effector T Cells That Then Migrate to the Tumor Site to Limit Cancer Development? This evidence concerns the gene CXCL9 and cancer.